Solutions
About Us
Insights
Careers

Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation. Chopra D, Lan Z, Waterhouse DM, Wolf J, Felip E, Moradian H, Karim N, Obiozor C, Stollenwerk B. Adv Ther. 2025

Epidemiology, patient management, and survival outcomes in resected patients with non-metastatic non-small cell lung cancer: a nationwide real-world study. Renaud S, Casabianca P, Diez-Andreu P, Chartier M, Gaudin AF, Bugnard F, Bénard S, Cotté FE, Chouaid C. BMC Cancer. 2025

Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison. Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Cruz IP, Hlavacek P. J Comp Eff Res. 2025

First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial. Jänne PA, Wang BC, Cho BC, Zhao J, Li J, Hochmair M, Peters S, Besse B, Pavlakis N, Neal JW, Kato T, Wu YL, Nguyen D, Lin J, Lin J, Vranceanu F, Szumski A, Lin HM, Fram RJ, Mok TSK. J Clin Oncol. 2025

Matching-Adjusted Indirect Comparison of Elranatamab versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma: Updated Results. Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Perez Cruz I, Hlavacek P. J Blood Med. 2025

Impact of age and time since diagnosis on thrombosis risk in myeloproliferative neoplasm patients: A nationwide register-based matched cohort study. Batyrbekova N, Hultcrantz M, Ravn Landtblom A, Szulkin R, Dickman PW, Andersson TM, Syriopoulou E. Br J Haematol. 2025

Real-world characteristics and outcomes of patients with multiple myeloma treated with belantamab mafodotin: a German claims data study. Luna J, d’Estrube T, Jacobsen A, Lehne M, Wellmann-Pichler B, Mevius A, Dornig S. Ann Hematol. 2025

Treatment Effect Estimation With Potential Outcomes for a Single-Arm Trial Compared With Historical Controls: A Case Study of Locally Recurrent Head and Neck Squamous Cell Carcinoma Patients Treated With Adjuvant Nivolumab. Harun N, Sparapani R, Laud PW, Sivaganesan S, Leddon JL, Haque S, Tang AL, Wise-Draper TM. Head Neck. 2025

Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Zamulko O, Karivedu V, Riaz MK, Monroe I, Romano A, Mulanda R, Kurtzweil N, Forsythe A, Allen CL, Harun N, Pan J, Rai S, El-Gamal D, Wise-Draper TM. Cancer Research Communications. 2025

Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study. Wheatley-Price P, Navani V, Pabani A, Routy B, Snow S, Denault MH, Kim Y, Syed I, Devost N, Hui D, Qadeer RA, Arora P, Velummailum R, Springford A, McKibbon C, Ho C. Lung Cancer. 2025